STING agonists have shown considerable promise in immunotherapy for tumors and chronic viral infections, whereas STING inhibitors have paved the way for novel treatments of inflammatory diseases, including NAFLD, ALD, IBD, and liver fibrosis. This evidence concerns the gene STING1 and inflammatory bowel disease.